Literature DB >> 641832

Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure.

C S Hudson, J E Rash, T N Tiedt, E X Albuquerque.   

Abstract

Brief and chronic exposure of rats to neostigmine methylsulfate produced marked morphological alterations of the fine structure at the end-plate region of the extensor digitorum longus muscles. These changes were dose and time dependent and were restricted primarily to the subjunctional myofibrillar apparatus and membrane-bound organelles. In addition, significant presynaptic alterations were observed including synaptic vesicle depletion and the appearance of numerous coated vesicles and membrane cisternae, which indicated continuing nerve terminal hyperactivity. With chronic treatment, degeneration and partial recovery of the nerve axon also were observed. The morphological changes of the end-plate region induced by neostigmine did not occur in most fibers after brief denervation and were eliminated entirely by chronic nerve section. Thus, the postsynaptic degenerative changes caused by neostigmine treatment observed in nondenervated animals appear to result primarily from greatly increased synaptic activity and not primarily from a direct neostigmine reaction with the pre- or postsynaptic membranes. Since the myopathic changes observed in this study were produced by neostigmine, a drug which is commonly employed in the routine treatment of human patients with myasthenia gravis, continued use of neostigmine for long-term therapy in noncrisis situations may not be accepted as being free from risk.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 641832

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  An expansion of Simons' integrated hypothesis of trigger point formation.

Authors:  Robert D Gerwin; Jan Dommerholt; Jay P Shah
Journal:  Curr Pain Headache Rep       Date:  2004-12

2.  The effect of chronic neostigmine treatment on channel properties at the rat skeletal neuromuscular junction.

Authors:  M Gwilt; D Wray
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

3.  Pathophysiological studies of neuromuscular function in subacute organophosphate poisoning induced by phosmet.

Authors:  J L Good; R K Khurana; R F Mayer; W M Cintra; E X Albuquerque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-03       Impact factor: 10.154

Review 4.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

6.  Synaptogenesis and myopathy under acetylcholinesterase overexpression.

Authors:  E Lev-Lehman; T Evron; R S Broide; E Meshorer; I Ariel; S Seidman; H Soreq
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

7.  A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis.

Authors:  C W Olanow; A S Wechsler; A D Roses
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

8.  Paucity of secondary synaptic clefts in a case of congenital myasthenia with multiple contractures: ultrastructural morphology of a developmental disorder.

Authors:  L M Smit; F G Jennekens; H Veldman; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

9.  Evaluation of the toxicity, pathology, and treatment of cyclohexylmethylphosphonofluoridate (CMPF) poisoning in rhesus monkeys.

Authors:  I Koplovitz; V C Gresham; L W Dochterman; A Kaminskis; J R Stewart
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

10.  Acute toxicity of cyclohexylmethylphosphonofluoridate (CMPF) in rhesus monkeys: serum biochemical and hematologic changes.

Authors:  G D Young; I Koplovitz
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.